Background: Cardiovascular disease (CVD) accounts for a significant portion of deaths in patients with COPD; however, evidence for early detection strategies for CVD in this population remain limited. Our paper aims to summarize existing data regarding subclinical CVD in patients with COPD with a view to identifying screening strategies in these patients. Methods: A systematic review of published literature was conducted for studies examining the relationship of COPD and markers of subclinical disease such as coronary artery calcification (CAC), carotid intima media thickness (cIMT), endothelial dysfunction, arterial stiffness as measured by pulse wave velocity (PWV) and augmentation indices (AIx). Both MEDLINE and EMBASE databases were searched till October 2015. Results: A total of 22 studies were included in the review. Compared with control subjects, patients with COPD had significantly higher cIMT (SMD 0.53, 95% CI 0.16-0.90), PWV (SMD 0.91, 95% CI 0.67-1.16) and AIx (SMD 0.86, 95% CI 0.52-1.19). Additionally, an overall higher prevalence of subclinical CVD as assessed by CAC, ABI and FMD was noted in our review. Conclusion: Although our findings need further evaluation in prospective studies, our review presents significant evidence in support of increased subclinical CVD burden in COPD patients independent of smoking status. Further large-scale casecontrol studies are required to highlight the significance of subclinical CVD screening in COPD patients.
Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States and is responsible for the cost of an estimated $49.9 billion, including $29.5 billion in direct medical expenditures in the United States in 2010. 1 Cardiovascular disease (CVD) has been increasingly recognized as the major cause of mortality and morbidity among patients with COPD. Cardiovascular events are prevalent in patients with COPD, and COPD doubles the risk of CVD mortality. 2 Additionally, the co-existence of COPD and CVD increases ER visits and hospitalization by as much as 62% when compared with COPD patients without CVD. 3 The relationship between COPD and CVD is not fully understood; however, the inflammatory mechanisms that are responsible for both COPD and CVD development may hold the link between these two disorders. 4, 5 A previous systematic review showed that patients with chronic airway limitation had significantly elevated levels of High Sensitivity C-reactive protein (hs-CRP), fibrinogen, tumor necrosis factor-a and leukocytes, suggesting persistent systemic inflammation in COPD patients. 5 Systemic inflammation has also been implicated in the development of atherosclerosis 6, 7 and elevated hs-CRP has been linked to increased risk of subsequent CVD. 8 Furthermore,
smoking is known to increase systemic inflammation and may be a common etiological factor uniting CVD and COPD. 9 However, FEV1, as a part of the GOLD criteria for classifying stages of COPD, is also an independent predictor of cardiovascular risk, which suggests that smoking, while detrimental, may not be the proximate cause of CVD in patients with COPD. 10, 11 Recently, great interest has been generated regarding measurements of subclinical vascular disease, such as coronary artery calcium (CAC), carotid intima-media thickness (cIMT), anklebrachial index (ABI) and markers of arterial stiffness and endothelial dysfunction, as tools to predict the risk of developing clinical CVD. [12] [13] [14] [15] [16] Despite their general validity, the usefulness of these markers in COPD patients is not as well established. The purpose of our review was to summarize the existing literature examining the relationship between COPD and measurements of subclinical vascular disease, and to inspect the utility of these measurements in monitoring subclinical cardiovascular changes in patients with COPD. Identifying the subset of COPD patients with a high risk of clinical CVD and targeting them for prevention efforts may lead to reduced COPD morbidity and mortality.
Methods
A systematic literature search was conducted on Medline via PubMed, and Embase, from inception until October 2015 by using both controlled vocabulary (MeSH and Emtree) terms and relevant free-text terms to identify relevant articles studying subclinical CVD markers in patients with COPD. Combinations of the following terms were used:
1. COPD, emphysema, chronic bronchitis, chronic obstructive pulmonary disease, chronic obstructive lung disease, obstructive pulmonary disease, obstructive airway disease, airway obstruction, airway limitation, 'pulmonary disease, chronic obstructive' and 'bronchitis, chronic'. 2. Carotid intima-media thickness, carotid intima media thickness and CIMT. 3. Ankle brachial index, ankle-brachial index, ankle brachial pressure index, ankle-brachial pressure index and ABI.
4. Coronary-artery calcium, coronary artery calcium and CAC. 5. Pulse wave velocity, pulse-wave velocity, pulse wave analysis, PWV, augmentation Index, augmented index, Alx, AI, cardio-ankle vascular index, cardio ankle vascular index and CAVI. 6. Flow mediated dilation, flow-mediated dilation and FMD.
The search yielded 300 unique citations, from which 52 relevant articles were selected. The selection strategy is outlined in Figure 1 . The relevant articles were then critically reviewed by three independent investigators, and the articles in question were discussed until a consensus was reached. Studies were included if they were original research articles written in English, examining COPD and various subclinical CVD markers. Case reports, review articles and studies without full texts available were excluded. Studies that recruited patients with clinical CVD or lacked control groups were also excluded. Data extracted from the final 16 studies included design, sample size, characteristics of patients and controls, main findings of the relevant CVD markers and appropriate statistical analyses. Data are presented as mean 6 standard deviation or median (interquartile range) as appropriate.
Results
A total of 22 studies were included in the review. Despite considerable variation in markers, COPD was associated with a higher atherosclerotic disease burden in the present review.
COPD and CIMT
Four studies measuring cIMT in patients with COPD were included in our review (Table 1) . [17] [18] [19] [20] All four studies found a significant association between COPD patients and increased cIMT. In one study, mean cIMT was found to be increased in the smoker COPD group compared with smoker controls (P ¼ 0.006), Figure 1 . Selection strategy. suggesting that COPD and smoking are independently associated with increased cIMT in these patients.
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COPD and pulse wave velocity All nine studies examining the association of COPD and PWV [21] [22] [23] [24] [25] [26] [27] [28] [29] found that COPD patients had significantly higher PWV than non-COPD patients (Table 1) . PWV was also found to be related to smoking status, 21 , COPD severity, 22, 26 exercise capacity, 21 , diastolic function 24 and step counts per day. 27 However, one study failed to find significantly different in PWVs of control smokers and control non-smokers. 28 Seven studies demonstrated a relationship of PWV with FEV1, although the nature of the relationship and the strength of the association varied across studies.
COPD and augmentation index
Three studies measuring augmentation index were included in the review (Table 1) . [23] [24] [25] All three studies showed a significantly elevated augmentation index in COPD patients. However, the sample sizes of these studies were very small.
COPD and CAC score
Four studies analyzing CAC in patients with COPD were included in the review (Table 1) , of which two demonstrated a significant association between CAC and COPD. [30] [31] [32] [33] Rasmussen et al. 31 (n ¼ 1535) reported that the presence of COPD was an independent predictor of being in a higher CAC group in patients with mild and moderate-to-severe COPD (P ¼ 0.04 and 0.02, respectively). COPD severity was found to have a significant linear relationship with CACS (P < 0.01). Williams et al. 32 (n ¼ 672) demonstrated higher mean CACS among COPD patients when compared with control smokers and control non-smokers respectively (P < 0.001). They also demonstrated a correlation of CACS with increased mortality in subjects with COPD. Two much smaller studies by Zagaceta et al. 30 and Gaisl et al., 33 however, failed to show a significant difference of CACS between COPD patients and controls (P ¼ 0.062 and P ¼ 0.893, respectively).
COPD and flow mediated dilatation
Three studies examining endothelial function in COPD patients were included in our review (Table 1) . [34] [35] [36] Eickhoff et al. 34 demonstrated that COPD patients had lower FMD in comparison with either control smokers or control non-smokers (P < 0.005 and P < 0.001, respectively). Moreover, FMD was positively correlated to percent predicted FEV1 and FEV1/FVC in all subjects (P < 0.001). Pizarro et al. 35 demonstrated a similar reduction in FMD in COPD patients versus controls (smokers and nonsmokers); however, COPD severity was not found to be associated FMD. Ives et al. 36 also showed the association between reduced FMD and COPD patients but smoking was not analyzed as a confounding factor despite the significant difference in smoking history between control and COPD patients.
COPD and ankle-brachial index
Three studies focused on the link between COPD and ABI, with one study demonstrating a higher prevalence of pathological ABI values in COPD patients as compared to smokers without COPD (Table 1) . 19, 21, 37 Castagna et al. 21 reported a higher prevalence of pathological ABI values (ABI < 0.9) in COPD patients versus control smokers and control non-smokers (P < 0.05). 
COPD and cardio-ankle vascular index
Aykan et al. 38 reported that COPD patients had significantly higher CAVI when compared with the controls (P < 0.001) and CAVI was inversely associated with percent predicted FEV1 (P < 0.001) ( Table 1 ). They also showed that CAVI was positively correlated to COPD stage (P < 0.001).
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COPD and smoking
Eleven of the twenty-two studies included in our review reported no significant difference of smoking history between patients and controls and did not address the link between subclinical markers and smoking. 17, 18, 20, [22] [23] [24] 27, 30, 31, 33, 38 Five studies, which compared COPD patients with control smokers, reported significant differences of targeted subclinical CVD markers independent of smoking history. 21, 28, 32, 34, 35 Four studies reported significant difference of smoking history between the COPD patients and controls; but did not assess its influence on cIMT. 19, 29, 36, 37 For the rest of the studies, both Albu et al. 25 and Cinarka et al. 26 reported no correlation between pack-years of smoking and PWV.
COPD severity and subclinical cardiovascular disease
The relationship between COPD severity and marker of subclinical CVD was assessed in 16 of the studies included in the review and is summarized in Table 2 . Seven studies demonstrated an association of severity of COPD with subclinical CVD markers. [21] [22] [23] 25, 26, 34, 38 . Five out of nine studies examining PWV demonstrated a significant association with severity of COPD. [21] [22] [23] 25, 26 None of the three studies in our review demonstrated an association of COPD severity with AIx. 22, 23, 25 Moreover, none of the two studies on CAC showed a significant association between COPD severity and CAC. 31, 32 Only one of the two studies on ABI found an association between COPD severity and ABI. 21 There were four studies that assessed the severity of COPD and its relationship with cIMT. One study demonstrated a relationship between COPD severity with cIMT in the overall population but not in patients, 17 another demonstrated only a univariate association between FEV1 and cIMT, 19 while the other two studies did not show an significant association between COPD severity and cIMT.
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Discussion
This systematic review provides evidence of an increased subclinical CVD burden in patients with COPD. In particular, cIMT, arterial stiffness (PWV and AIx), endothelial function (FMD) and peripheral vascular disease (ABI and CAVI) were altered in patients with COPD as compared with controls. COPD was associated with a higher burden of CAC in two studies, whereas the other two studies were equivocal, probably due to smaller sample sizes. There was also evidence that the severity of COPD, measured through FEV1, was associated with subclinical CVD measurements; however, this was not uniformly observed across studies in our review.
In line with our review, other studies have established a link between symptomatic CVD and COPD. Mullerova et al. 39 demonstrated that patients with COPD had as much as a 70% increase in the prevalence of unspecified CVD; between 7 and 31% increase in the prevalence of congestive heart failure; and up to 60% increase in the prevalence of coronary heart disease. To extend the study by Mullerova et al, Chen et al. 40 conducted a meta-analysis of 27 datasets and reported a 2.5 times increased risk of cardiovascular disease overall and a two to five times higher risk of major cardiovascular disease types, including ischemic heart disease, cardiac dysrhythmia, heart failure, diseases of the pulmonary circulation and arterial diseases. The literature review published by Claudio Ferri, 41 on the contrary, focused on strategies to reduce the risk of CVD in patients with COPD and suggested glycopyrronium as an effective long-acting anticholinergic bronchodilator with no increase in CVD risk for patients with COPD. However, instead of studying the considerable evidence of the association between CVD and COPD, our systematic review focused on the subclinical markers that have predictive value of CVD in the hope that future studies can use these markers to develop reliable cardiovascular risk stratification for patients with COPD. Systemic inflammation, a common clinical presentation of COPD, may account for the increased prevalence of CVD in patients with COPD. Several studies have showed that there is a relationship between COPD and inflammatory markers such as hs-CRP, fibrinogen, leucocytes and TNF-a. 5 In addition, worsening systemic inflammation is associated with COPD severity 42 and systemic inflammation is related to greater morbidity and mortality in COPD. 43 The importance of inflammation in the process of atherosclerotic disease has also been well acknowledged. 6, 7, [44] [45] [46] [47] [48] One of the best studied markers is hs-CRP which has been shown in multiple studies to be independently associated with incident coronary events after adjusting. [49] [50] [51] Although inflammation may be an epiphenomenon rather than a cause of atherosclerosis, the presence of a higher inflammatory burden in COPD patients offers supporting evidence for increased CVD risk.
Smoking is a potential confounder in the association between COPD and subclinical CVD due to its strong association with both disease conditions. However, the majority of the studies in this review controlled for the confounding effect of smoking status or analyzed the relationship between smoking and targeted markers or account for the influence of smoking in the study design. Thus, our conclusions are not significantly impacted by the potential confounding that smoking creates.
COPD severity is an important consideration when assessing CVD risk, considering COPD has significant extra-pulmonary morbidities. 52 A number of studies in our review demonstrated that patients with more severe COPD had a greater burden of subclinical CVD. 22, 25, 26, 31, 38 Curkendall et al. 53 also reported that CVD mortality and morbidity was increased with increasing severity of COPD, which is consistent with our findings. Moreover, a decrease in FEV1 was independently associated with a higher burden of subclinical CVD in the literature 54, 55 as well as in some studies included in our review. 17, 22, 23, [25] [26] [27] 34, 38 Several limitations of our review should be noted. First, the majority of the studies had relatively small sample sizes, which limits the reliability of their observations and the subsequent generalizability of our analyses. Second, most of the studies in our review did not exclude subjects with traditional cardiovascular risk factors. However, no significant difference of traditional cardiovascular risk factors between COPD patients and controls were noted in any studies. Thirdly, most studies were case-control studies and not cohort studies, which limited our ability to make conclusions about temporality.
Our review has a number of strengths. First, the variety of markers included in our review enable us to make a stronger determination about overall subclinical CVD burden instead of studies examining a single marker at a time. Second, majority of the studies adjusted for the effect of smoking status on CVD markers, which makes our findings relatively specific to COPD. Third, our review summarized the association between COPD severity and subclinical CVD markers reported by studies included in our paper, which may provide a useful insight into the pathophysiology between COPD and CVD.
Conclusion
Our review suggests that there is an increased burden of subclinical CVD in COPD patients as assessed by a variety of markers. In our review, PWV, AIx and cIMT were most consistently altered in COPD patients, suggesting that these markers may perhaps be useful tools of risk stratification in COPD patients. However, the relative paucity of published data assessing the role of these markers in COPD patients makes them a pertinent target for future research, and long-term studies to validate this association are essential to determine the true utility of these markers in risk stratification.
For clinicians, our review provides substantive evidence that patients with COPD have a higher subclinical atherosclerotic disease burden. This, in tandem with published literature linking COPD with clinical CVD, provides further evidence of increased CVD risk. It is reasonable to conclude that clinicians should maintain a relatively high index of suspicion for the development of CVD events in patients with COPD, while awaiting the results of larger trials.
